NovaCina is a Drug Product CDMO based in Perth, Australia, providing Global Services. The site was previously owned by Pfizer for over 20 years, and was acquired by the Bridgewest Group, in April 2023.

We provide an array of services for complex sterile clinical supplies, as well as, for branded and generic commercial supplies for the Global market. Our services include (for small and large molecules):

• Analytical Method Development and Formulation Development
• Process Development (including scale up and optimisation)
• Drug Product sterile GMP Manufacturing for Clinical and Commercial supplies (we can
fill into Blow-Fill-Seal, vials, PFS and soon to be cartridges)
• Full QC and QA services.

NovaCina can handle cytotoxic compounds, and also has a controlled drug license.

The site team are highly experienced and knowledgeable, with an average tenure of 15 years.

The site also has an incredible strong regulatory history, with approvals from seven bodies, including TGA, USFDA and Europe.